Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30838033 | 0.90 | PKM (0.43) | CYP11B2CYP11B1MAPK1TNFIL1B | |
| Formic Acid SCHEMBL30838062 | 0.78 | IL1B (0.38) | CYP11B2CYP11B1MAPK1IL1B | |
| Hydrochloric Acid SCHEMBL30838035 | 0.78 | IDH2 (0.48) | CHEK1MAPK1 | |
| SCHEMBL27095188 | 0.76 | CHEK1 (0.38) | CHEK1FLT3CYP11B2CYP11B1MAPK1 | |
| SCHEMBL27142315 | 0.76 | CHEK1 (0.38) | CHEK1FLT3CYP11B2CYP11B1MAPK1 | |
| SCHEMBL30838084 | 0.76 | CYP11B1 (0.41) | FLT3CYP11B2CYP11B1 | |
| SCHEMBL27095187 | 0.76 | CHEK1 (0.38) | CHEK1FLT3CYP11B2CYP11B1MAPK1 | |
| Formic Acid SCHEMBL30838019 | 0.76 | HTR3A (0.42) | CHEK1CYP11B2CYP11B1 | |
| SCHEMBL24288074 | 0.76 | CYP11B2 (0.36) | CYP11B2CYP11B1MAPK1 | |
| Hydrochloric Acid SCHEMBL30838016 | 0.76 | IDH2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CHRNA6, CHRM2, CHRNA1 | CHEK1 1012/4885FLT3 1260/4885CYP11B2 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.